Welcome to our dedicated page for Xenon Pharmaceuticals SEC filings (Ticker: XENE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Xenon Pharmaceuticals's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Xenon Pharmaceuticals's regulatory disclosures and financial reporting.
FMR LLC filed Amendment No. 8 to a Schedule 13G reporting its beneficial ownership of common stock of Xenon Pharmaceuticals Inc. FMR LLC reports beneficial ownership of 9,959,795.17 shares of common stock, representing 10.3% of the class. It reports sole voting power over 9,951,732.00 shares and sole dispositive power over 9,959,795.17 shares, with no shared voting or dispositive power. Abigail P. Johnson is also listed as a reporting person with sole dispositive power over the same 9,959,795.17 shares and no voting power. The filing notes that one or more other persons may have rights to receive dividends or sale proceeds from these securities, but no such person has an interest exceeding five percent of Xenon’s outstanding common stock.
Xenon Pharmaceuticals Inc. reported second-quarter 2026 results marked by higher operating losses as it advances late-stage neurology programs. For the quarter, net loss was $110.7 million, and for the first half of 2026 net loss totaled $213.0 million, with no collaboration revenue versus $7.5 million a year earlier.
Research and development expense rose to $99.2 million in Q2 and $187.7 million for the first half, driven mainly by Phase 3 studies of azetukalner in epilepsy and mood disorders and early-stage pain programs. General and administrative expense reached $47.8 million for the half. Cash, cash equivalents and marketable securities were $1.25 billion as of June 30, 2026, bolstered by an $130.0 million ATM issuance and a $707.6 million underwritten equity and pre-funded warrant offering. Management states this liquidity is expected to fund operations for at least 12 months. The company plans to submit an NDA for azetukalner in focal onset seizures in the third quarter of 2026 and continues multiple Phase 3 and Phase 1 trials across epilepsy, depression and pain.
Xenon Pharmaceuticals reported Q2 2026 results alongside significant clinical and regulatory progress for its lead KV7 modulator azetukalner. After a successful pre-NDA meeting with the FDA, the company plans to submit a New Drug Application for azetukalner in focal onset seizures in the third quarter of 2026. Phase 3 trials continue across epilepsy (X-TOLE3, X-ACKT), major depressive disorder (X-NOVA2 and X-NOVA3) and bipolar depression (X-CEED), with topline X-NOVA2 data anticipated in the first half of 2027.
Cash, cash equivalents and marketable securities totaled $1,245.1 million as of June 30, 2026, compared with $586.0 million as of December 31, 2025, and management expects this to fund operations into 2029. For Q2 2026, Xenon reported a net loss of $110.7 million and no revenue, versus a $84.7 million net loss in Q2 2025, as research and development expenses increased to $99.2 million and general and administrative expenses to $23.9 million, driven by late-stage azetukalner programs, pain studies, manufacturing, and higher personnel costs. Other income rose to $11.8 million, primarily from higher interest income, and 96,752,884 common shares and 2,931,293 pre-funded warrants were outstanding as of June 30, 2026.
FMR LLC reported its beneficial ownership of common stock of Xenon Pharmaceuticals Inc. as of June 30, 2026. FMR LLC beneficially owned 9,599,498 shares of common stock, representing 9.9% of the class, with sole dispositive power over all such shares and sole voting power over 9,591,437 shares.
Abigail P. Johnson is also listed as a reporting person with sole dispositive power over the same 9,599,498 shares and no voting power. The securities are held on behalf of underlying clients and other persons who have rights to dividends or sale proceeds, but no other single person has an interest in more than five percent of the outstanding common stock.
Xenon Pharmaceuticals director Gary Patou reported an open-market sale of 1,322 Common Shares of Xenon Pharmaceuticals Inc. at $53.14 per share on June 5, 2026. After this transaction, he directly holds 24,896 Common Shares and has an additional 4,902 Common Shares held indirectly.
The filing notes that the sales were effected under a Rule 10b5-1 trading plan adopted on August 17, 2025, established solely to cover income tax obligations related to the vesting of restricted stock units granted on June 5, 2025. This indicates the sale was pre-planned and tied to tax liabilities rather than a discretionary trade.
Xenon Pharmaceuticals Inc. director Gillian Cannon reported an open-market sale of common shares. On June 5, 2026, she sold 1,190 Common Shares at an average price of $53.14 per share and now directly holds 1,455 shares.
According to a footnote, these sales were made under a pre-arranged Rule 10b5-1 trading plan adopted on August 15, 2025, and were executed solely to cover income tax obligations arising from the vesting of RSUs granted on June 5, 2025.
PATOU GARY reported acquisition or exercise transactions in this Form 4 filing.
Xenon Pharmaceuticals director Gary Patou reported several equity compensation moves. He received a grant of 1,593 restricted share units (RSUs) and a separate grant of 10,507 share options with a strike price of $53.4600 per share expiring on June 2, 2036. Earlier, on June 1, 2026, 2,645 RSUs from a prior award vested 100% and were settled into the same number of common shares, lifting his direct common share holdings to 26,218 shares. The filing also shows 4,902 common shares held indirectly through the Gary & Karen Barbara Patou trustees of the Patou Family Trust.
Xenon Pharmaceuticals Inc. director Patrick Machado reported multiple equity awards and an option exercise. On June 1, 2026, 2,645 Restricted Share Units (RSUs) vested, converting into 2,645 Common Shares, all held directly. On June 3, 2026, he received 1,593 additional RSUs and an option grant for 10,507 shares with a $53.4600 exercise price, expiring on June 2, 2036. The newly granted RSUs and options are scheduled to vest or become exercisable in connection with the issuer’s 2027 annual meeting of shareholders.